Evidence map›Paper›PMID 39916484›Full record

ArticleActa dermato-venereologica2025

Sex Disparities of Health-related Quality of Life in Moderate to Severe Psoriasis: A Real-world Analysis from the Swiss Psoriasis Registry (SDNTT).

Ramtin Lichtenberger, Lara Valeska Maul, Ion Birkenmaier, Iker Oyanguren, Melike Ak, Kristine Heidemeyer, Christoph Schlapbach, Nikhil Yawalkar, Alexander Egeberg, Simon Francis Thomsen and 11 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta dermato-venereologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Ramtin LichtenbergerDepartment of Dermatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-7682-0238
Lara Valeska MaulDepartment of Dermatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Ion BirkenmaierDepartment of Dermatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland; Life Science Zurich Graduate School, Faculty of Science, University of Zurich, Zurich, Switzerland.
Iker OyangurenSwiss4ward, Statistician and Data Analyst, Zurich, Switzerland.
Melike AkDepartment of Dermatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Kristine HeidemeyerDepartment of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Christoph SchlapbachDepartment of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Nikhil YawalkarDepartment of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Alexander EgebergDepartment of Dermato-Venereology & Wound Healing Centre, Bispebjerg Hospital, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Simon Francis ThomsenDepartment of Dermato-Venereology & Wound Healing Centre, Bispebjerg Hospital, Copenhagen, Denmark.
Jacob P ThyssenDepartment of Dermato-Venereology & Wound Healing Centre, Bispebjerg Hospital, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Christina SorbeInstitute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
Wolf-Henning BoehnckeDivision of Dermatology and Venereology, Geneva University Hospitals, Geneva, Switzerland.
Curdin ConradDepartment of Dermatology, University Hospital Lausanne, Lausanne, Switzerland.
Antonio CozzioDepartment of Dermatology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Georgios KokolakisPsoriasis Research and Treatment Center, Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Raphael MicheroliDepartment of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Jashin J WuDepartment of Dermatology, University of Miami Miller School of Medicine, Miami, USA.
Thomas KündigDepartment of Dermatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland; Faculty of Medicine, University of Zurich, Zurich, Switzerland.
Alexander NavariniDepartment of Dermatology, University Hospital Basel, University of Basel, Basel, Switzerland.
Julia-Tatjana MaulDepartment of Dermatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland; Faculty of Medicine, University of Zurich, Zurich, Switzerland. julia-tatjana.maul@usz.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Real-world data on gender differences in quality of life among psoriasis patients before and during treatment are scarce. This study analysed data of 748 adults with moderate-to-severe psoriasis enrolled in the Swiss Dermatology Network of Targeted Therapy registry between 2011 and 2023. Quality of life was assessed using the Dermatological Life Quality Index at baseline and at 3, 6, 12, 18, and 24 months. At baseline, women reported significantly lower quality of life than men, with higher Dermatological Life Quality Index scores in the IL-17 inhibitor group (15.0 vs 11.0, p = 0.027), IL-12/23 inhibitor group (7.5 vs 7.0, p = 0.049), and non-biologic therapy group (13.0 vs 9.0, p < 0.001). Although quality of life improved across all subgroups during the follow-up period, women treated with IL-12/23 inhibitors continued to report worse quality of life compared with men after 2 years (p < 0.05), while no significant differences were observed with other therapies. These findings emphasize that women with psoriasis experience lower quality of life at treatment initiation and throughout non-biologic and biologic therapies, underlining the importance of addressing gender-specific differences in the management of psoriasis.

Indexed as

Health Status DisparitiesPsoriasisQuality of LifeAdultAgedBiological ProductsDermatologic AgentsFemaleHumansMaleMiddle AgedRegistriesSeverity of Illness IndexSex FactorsSwitzerlandTime FactorsBiological ProductsDermatologic Agents

Identifiers

PMID39916484
PMCPMC11833253

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.